Related Experiment Video

Updated: Jan 3, 2026

In Vitro Modeling of Down Syndrome Neurogenesis Using Human-Induced Pluripotent Stem Cells
06:38

In Vitro Modeling of Down Syndrome Neurogenesis Using Human-Induced Pluripotent Stem Cells

Published on: March 7, 2025

904

Pharmacotherapy of Down's Syndrome: When and Which?

Seyed K Tayebati1, Alessandro Cecchi2, Ilenia Martinelli1

  • 1School of Medicinal Sciences and Health Products, University of Camerino, Camerino, Italy.

CNS & Neurological Disorders Drug Targets
|November 15, 2019
PubMed

Insights

Research on Down syndrome (DS) treatments in mice shows promise for prenatal interventions. Further research is needed to improve quality of life and address ethical considerations for DS patients.

Area of Science:

  • Genetics
  • Developmental Biology
  • Pharmacology

Background:

  • Down syndrome (DS) is a genetic disorder affecting multiple body systems, including cognitive function.
  • Current postnatal treatments for DS complications offer limited improvements in quality of life.
  • Emerging strategies explore prenatal interventions for DS.

Purpose of the Study:

  • To review outcomes of Down syndrome treatments in the Ts65Dn mouse model.
  • To evaluate the efficacy of various therapeutic strategies for DS.
  • To discuss the ethical implications of prenatal DS treatment.

Main Methods:

  • Review of studies utilizing the Ts65Dn mouse model for Down syndrome research.
  • Analysis of treatment outcomes from genetic modification, vasoactive intestinal peptide derivatives, and fluoxetine administration.
  • Examination of ethical considerations surrounding prenatal diagnosis and treatment of DS.

Main Results:

  • The Ts65Dn mouse model provides valuable insights into DS pathogenesis and treatment efficacy.
  • Investigated treatments like genetic modification and pharmacological interventions show potential but require further development.
  • Significant ethical challenges exist regarding prenatal diagnosis and intervention for DS.

Conclusions:

  • Prenatal treatment strategies for Down syndrome warrant further investigation, particularly using animal models like the Ts65Dn mouse.
  • Improving the quality of life for individuals with DS is paramount and may help navigate ethical dilemmas.
  • Continued research efforts are crucial for advancing Down syndrome therapies and addressing associated ethical concerns.

Keywords:
DS-induced disordersDown’s syndromeanimal modelsassociated disorderspharmacotherapyprenatal and postnatal therapies.

More Related Videos

A Treatment Package without Escape Extinction to Address Food Selectivity04:23

A Treatment Package without Escape Extinction to Address Food Selectivity

Published on: August 21, 2015

12.0K
Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans07:35

Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans

Published on: February 4, 2014

11.9K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
177
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
223
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
718
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
415
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
905
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
158